SCHEMBL2289541

SCHEMBL2289541

COc1cc(Cl)c(-c2nc3ccc(F)cn3c2Nc2c(C)cccc2C)c(OCC(N)=O)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.41
GAA P10253 10/20 0.40
MAPT P10636 8/20 0.40
TP53 P04637 4/20 0.36
THRB P10828 1/20 0.36
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
GLA P06280 1/20 0.35
RAB9A P51151 1/20 0.35
HPGD P15428 1/20 0.35
CHRNA7 P36544 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
POLB P06746 2/20 0.35
CNR2 P34972 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2289183 0.93 TRPA1 (0.42) TRPA1GAAMAPTTP53THRB
SCHEMBL2292813 0.93 TRPA1 (0.42) TRPA1GAAMAPTTP53THRB
SCHEMBL2294986 0.92 TRPA1 (0.40) TRPA1GAAMAPTTP53LMNA
SCHEMBL2291979 0.92 TRPA1 (0.39) TRPA1GAAMAPTTP53THRB
SCHEMBL2287599 0.91 GAA (0.41) TRPA1GAAMAPTTP53THRB
SCHEMBL2292332 0.91 TRPA1 (0.41) TRPA1GAAMAPTTP53LMNA
SCHEMBL2287034 0.91 GAA (0.41) TRPA1GAAMAPTTP53THRB
SCHEMBL2295321 0.90 GAA (0.39) TRPA1GAAMAPTTP53THRB
SCHEMBL2291138 0.90 TRPA1 (0.38) TRPA1GAAMAPTTP53LMNA
SCHEMBL2288415 0.90 TRPA1 (0.41) TRPA1GAAMAPTTP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US claimed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US claimed
EP-2032571-A1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS Merck Patent GmbH (DE) 2009-03-11 EP claimed
WO-2007147478-A1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2007-12-27 WO claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US disclosed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 TRPA1 1229/4885GAA 1202/4885MAPT 1138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.